
1. plos negl trop dis. 2017 aug 22;11(8):e0005805. doi:
10.1371/journal.pntd.0005805. ecollection 2017 aug.

mitochondria lipid raft-located fof1-atp synthase major therapeutic
targets antileishmanial anticancer activities ether lipid
edelfosine.

villa-pulgarín ja(1), gajate c(1)(2), botet j(3), jimenez a(3), justies n(4),
varela-m re(1), cuesta-marbán á(1), müller i(5), modolell m(4), revuelta jl(3),
mollinedo f(1)(2).

author information: 
(1)instituto de biología molecular celular del cáncer, centro de investigación 
del cáncer, consejo superior de investigaciones científicas (csic)-universidad de
salamanca, campus miguel de unamuno, salamanca, spain.
(2)laboratory cell death cancer therapy, department cellular and
molecular medicine, centro de investigaciones biológicas, consejo superior de
investigaciones científicas (csic), madrid, spain.
(3)metabolic engineering group, departamento de microbiología genética,
universidad de salamanca, edificio departamental, campus miguel de unamuno,
salamanca, spain.
(4)department cellular immunology, max-planck-institut für immunbiologie und
epigenetik, freiburg, germany.
(5)department medicine, section immunology, st. mary's campus, imperial
college london, london, united kingdom.

background: leishmaniasis world's second deadliest parasitic disease after
malaria, current treatment different forms disease far from
satisfactory. alkylphospholipid analogs (apls) family anticancer drugs
that show antileishmanial activity, including first oral drug (miltefosine)
for leishmaniasis drugs preclinical/clinical oncology trials, their
precise mechanism action remains elucidated.
methodology/principal findings: show tumor cell
apoptosis-inducer edelfosine effective apl, compared to
miltefosine, perifosine erucylphosphocholine, killing leishmania spp.
promastigotes amastigotes well tumor cells, assessed dna
breakdown determined flow cytometry. studies using animal models, found 
that orally-administered edelfosine showed potent vivo antileishmanial
activity diminished macrophage pro-inflammatory responses. edelfosine was
also able kill leishmania axenic amastigotes. edelfosine taken host 
macrophages killed intracellular leishmania amastigotes infected
macrophages. edelfosine accumulated tumor cell mitochondria leishmania
kinetoplast-mitochondrion, led mitochondrial transmembrane potential
disruption, successive breakdown parasite mitochondrial nuclear
dna. ectopic expression bcl-xl inhibited edelfosine-induced cell death both
leishmania parasites tumor cells. found cytotoxic activity of
edelfosine leishmania parasites tumor cells associated a
dramatic recruitment fof1-atp synthase lipid rafts following edelfosine
treatment parasites cancer cells. raft disruption specific
fof1-atp synthase inhibition hindered edelfosine-induced cell death both
leishmania parasites tumor cells. genetic deletion fof1-atp synthase led
to edelfosine drug resistance saccharomyces cerevisiae yeast.
conclusions/significance: present study shows antileishmanial and
anticancer actions edelfosine share common signaling processes, with
mitochondria raft-located fof1-atp synthase critical killing
process, thus identifying novel druggable targets treatment of
leishmaniasis.

doi: 10.1371/journal.pntd.0005805 
pmcid: pmc5568728
pmid: 28829771  [indexed medline]

